Merck KGaA said on Tuesday that Allan Gabor will succeed Alasdair Jelfs as managing director for the company in China as of Feb. 1, 2018.
The German company said Mr. Gabor would also take over operational responsibility for the performance materials business in China.
Additionally, Mr. Gabor will become a permanent member of the performance materials leadership team, Merck KGaA said.
Mr. Jelfs take up duties at company headquarters in Darmstadt, Germany, the company said.
Mr. Gabor joined Merck KGaA in 2013, and is currently head of the biopharma business in Asia, including China. Prior to joining the company, Mr. Gabor was head of Pfizer in China.
By Marc Navarro Gonzalez
Source: Dow Jones Newswires via Fox Business
Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.
StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.
In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.
